Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 13-20

  Roehrborn, Claus G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   McConnell, John ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Bonilla, Jaime ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Rosenblatt, Sidney ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Hudson, Perry B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Malek, Gholem H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Schellhammer, Paul F ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Bruskewitz, Reginald ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Matsumoto, Alvin M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Harrison, Lloyd H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Fuselier, Harold A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Walsh, Patrick ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Roy, Johnny ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Andriole, Gerald ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Resnick, Martin ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Waldstreicher, Joanne ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Jackson Foundation   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ OCHSNER CLINIC FOUNDATION   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

^k UNIVERSITY OF OKLAHOMA   (United States)

^l WASHINGTON UNIVERSITY   (United States)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Magnetic resonance imaging; Prostate; Prostate specific antigen; Prostatic hyperplasia

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; URINE RETENTION;

EID: 0033992288     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67962-1     Document Type: Article

References (26)

1. Guess, H. A., Arrighi, H. M., Metter, E. J. et al: Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate, 17: 241, 1990.
2. Barry, M. J., Fowler, F. J., O'Leary, M. P. et al: The American Urologlcal Association symptom index for benign prostatic hyperplasia. J Urol 148: 1549, 1992.
3. Barry, M. J. and O'Leary, M. P.: Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am, 22: 299, 1995.
4. Barry, M. J., Fowler, F. J., Jr., O'Leary, M. P. et al: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care, 33: AS145, 1995.
5. Cockett, A. T. K., Khoury, S., Aso, Y. et al: The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands: Scientific Communication International Ltd., 1996.
6. Abrams, P. H.: Prostatism and prostatectomy: the value of urine flow rate measurement in the preoperative assessment for operation. J Urol 117: 70, 1977.
7. Jensen, K. M., Jorgensen, J. B. and Mogensen, P.: Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand J Urol Nephrol, 22: 109, 1988.
8. Jensen, K. M., Jorgensen, J. B. and Mogensen, P.: Urodynamics in prostatism. IV. Search for prognostic patterns as evaluated by linear discriminant analysis. Scand J Urol Nephrol, suppl. 114: 84, 1988.
9. Jensen, K. M., Jorgensen, J. B. and Mogensen, P.: Urodynamics in prostatism. II. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol, suppl, 114: 72, 1988.
10. Chancellor, M. B., Blaivas, J. G., Kaplan, S. A. et al: Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J Urol, 145: 810, 1991.
11. Barry, M. J., Cockett, A. T., Holtgrewe, H. L. et al: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol, 150: 351, 1993.
12. McConnell, J. D., Barry, M. J., Bruskewitz, R. C. et al: Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline. In: No. 8. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service. U.S. Department of Health and Human Services, 1994.
13. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., et al: The establishment of age specific reference ranges for prostate specific antigen. J Urol, 149: 510A, abstract 1188, 1993.
14. Boyle, P., Gould, A. L. and Roehrborn, C. G.: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 48: 398, 1996.
15. Jacobsen, S. J., Jacobson, D. J., Girman, C. J. et al: Natural history of prostatism: risk factors for acute urinary retention. J Urol, 158: 481, 1997.
16. Roehrborn, C. G., McConnell, J. D., Lieber, M. et al: Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology, 53: 473, 1999.
17. Ronilla, J., Stoner, E., Grino, P. et al: Intra- and interobserver variability of MRI prostate volume measurements. Prostate, 31: 98, 1997.
18. McConnell, J. D., Bruskewitz, R., Walsh, P. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med, 338: 557, 1998.
19. Rhodes, T., Girman, C. J., Jacobsen, S. J., et al: Longitudinal measures of prostate volume in a community-based sample: 3.5 year followup in the Olmsted County study of health status and Urinary symptoms among men. J Urol, 153: 301A, abstract 291, 1995.
20. Jacobsen, S. J., Girman, C. J., Guess, H. A. et al: Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology, 45: 64, 1995.
21. Kaplan, S. A., Te, A. E., Pressler, L. B. et al: Transition zone index (TZI) as a method of assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure. J Urol, 154: 1764, 1995.
22. Andersen, J. T., Ekman, P., Wolf, H. et al: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology, 46: 631, 1995.
23. Nickel, J. C., Fradet, Y., Boake, R. C. et al: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J, 155: 1251, 1996.
24. Roehrborn, C. G., Oesterling, J. E., Auerbach, S. et al: Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology, 47: 159, 1996.
25. Collins, G. N., Raab, G. M., Hehir, M. et al: Observer variability and reproducibility of transrectal ultrasound in the measurement of prostate volume. Ultrasound Med Biol 21: 1101, 1995.
26. Lepor, H., Williford, W. O., Barry, M. J. et al. A randomized placebo controlled clinical trial of the safety and efficacy of therapies in men with clinical benign prostatic hyperplasia. N Engl J Med, 335: 533, 1996.